114 related articles for article (PubMed ID: 19027046)
1. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial.
Groth N; Montomoli E; Gentile C; Manini I; Bugarini R; Podda A
Vaccine; 2009 Jan; 27(5):786-91. PubMed ID: 19027046
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
Szymczakiewicz-Multanowska A; Groth N; Bugarini R; Lattanzi M; Casula D; Hilbert A; Tsai T; Podda A
J Infect Dis; 2009 Sep; 200(6):841-8. PubMed ID: 19673651
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N
Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
[TBL] [Abstract][Full Text] [Related]
4. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine.
Ambrozaitis A; Groth N; Bugarini R; Sparacio V; Podda A; Lattanzi M
Vaccine; 2009 Oct; 27(43):6022-9. PubMed ID: 19666152
[TBL] [Abstract][Full Text] [Related]
5. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
Reisinger KS; Block SL; Izu A; Groth N; Holmes SJ
J Infect Dis; 2009 Sep; 200(6):849-57. PubMed ID: 19673652
[TBL] [Abstract][Full Text] [Related]
6. Trivalent inactivated subunit influenza vaccine Influvac: 25-Year experience of safety and immunogenicity.
Giezeman KM; Nauta J; de Bruijn IA; Palache AM
Vaccine; 2009 Apr; 27(18):2414-7. PubMed ID: 19368782
[TBL] [Abstract][Full Text] [Related]
7. Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons.
Szymczakiewicz-Multanowska A; Lattanzi M; Izu A; Casula D; Sparacio M; Kovacs C; Groth N
Hum Vaccin Immunother; 2012 May; 8(5):645-52. PubMed ID: 22418809
[TBL] [Abstract][Full Text] [Related]
8. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.
Lina B; Fletcher MA; Valette M; Saliou P; Aymard M
Biologicals; 2000 Jun; 28(2):95-103. PubMed ID: 10885616
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of two subunit influenza vaccines in healthy children, adults and the elderly: a randomized controlled trial in China.
Zhu FC; Zhou W; Pan H; Lu L; Gerez L; Nauta J; Giezeman K; de Bruijn I
Vaccine; 2008 Aug; 26(35):4579-84. PubMed ID: 18602729
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial comparing split and subunit influenza vaccines in adults in Colombia.
Morales A; Arias Salazar J; Salazar Y; García A; Arnoux S; Arancibia A; Deroche C; Rey E
Medicina (B Aires); 2003; 63(3):197-204. PubMed ID: 12876902
[TBL] [Abstract][Full Text] [Related]
12. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).
Doroshenko A; Halperin SA
Expert Rev Vaccines; 2009 Jun; 8(6):679-88. PubMed ID: 19485748
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
[TBL] [Abstract][Full Text] [Related]
14. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
[TBL] [Abstract][Full Text] [Related]
15. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
[TBL] [Abstract][Full Text] [Related]
16. A Phase I, randomized controlled clinical trial to study the reactogenicity and immunogenicity of a new split influenza vaccine derived from a non-tumorigenic cell line.
Percheson PB; Trépanier P; Dugré R; Mabrouk T
Dev Biol Stand; 1999; 98():127-32; discussion 133-4. PubMed ID: 10494965
[TBL] [Abstract][Full Text] [Related]
17. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
Li RC; Fang HH; Li YP; Liu YP; Nong Y; Huang GB
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):548-51. PubMed ID: 19040034
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip.
Delore V; Salamand C; Marsh G; Arnoux S; Pepin S; Saliou P
Vaccine; 2006 Mar; 24(10):1586-92. PubMed ID: 16271424
[TBL] [Abstract][Full Text] [Related]
19. Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies.
Palache AM; Scheepers HS; de Regt V; van Ewijk P; Baljet M; Brands R; van Scharrenburg GJ
Dev Biol Stand; 1999; 98():115-25; discussion 133-4. PubMed ID: 10494964
[No Abstract] [Full Text] [Related]
20. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.
Engler RJ; Nelson MR; Klote MM; VanRaden MJ; Huang CY; Cox NJ; Klimov A; Keitel WA; Nichol KL; Carr WW; Treanor JJ;
Arch Intern Med; 2008 Dec; 168(22):2405-14. PubMed ID: 19064822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
